Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease.
about
Deubiquitylating enzymes and diseaseParkin ubiquitinates and promotes the degradation of RanBP2USP17 regulates Ras activation and cell proliferation by blocking RCE1 activityMutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson diseaseMitochondria: A Therapeutic Target for Parkinson's Disease?The aetiology of idiopathic Parkinson's diseaseCombining biochemical and imaging markers to improve diagnosis and characterization of mild traumatic brain injury in the acute setting: results from a pilot studyUbiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats.Expression of nicotinamide N-methyltransferase (E.C. 2.1.1.1) in the Parkinsonian brain.Parkinson's disease: Exit toxins, enter geneticsACT and UCH-L1 polymorphisms in Parkinson's disease and age of onset.Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegenerationThe genetic basis of Parkinson's diseaseTransgenic animal models of neurodegeneration based on human genetic studies.Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury.Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injuryCombination therapies: The next logical Step for the treatment of synucleinopathies?Whole exome sequencing of rare variants in EIF4G1 and VPS35 in Parkinson diseaseTargeting the progression of Parkinson's disease.Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's Disease: a HuGE review and meta-analysis.Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.Biomarkers for the clinical differential diagnosis in traumatic brain injury--a systematic review.The challenge of mild traumatic brain injury: role of biochemical markers in diagnosis of brain damage.Association between ubiquitin carboxy-terminal hydrolase-L1 S18Y variant and risk of Parkinson's disease: the impact of ethnicity and onset age.The Next Generation of Biomarker Research in Spinal Cord Injury.Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues.Detection of ubiquityl-calmodulin conjugates with a novel high-molecular weight ubiquitylprotein-isopeptidase in rabbit tissues.Biochemical changes in the injured brain.Porcine UCHL1: genomic organization, chromosome localization and expression analysis.Selective neuroprotective effects of the S18Y polymorphic variant of UCH-L1 in the dopaminergic system.Drosophila Ubiquitin C-Terminal Hydrolase Knockdown Model of Parkinson's Disease.S18Y polymorphism in the UCH-L1 gene and Parkinson's disease: Evidence for an age-dependent relationshipUbiquitin C-terminal Hydrolase L1 Regulates Lipid Raft-dependent Endocytosis
P2860
Q21284381-42B2020E-CE71-43F8-B6B7-AFBFB15F3693Q24298223-077692DE-17BB-4854-B336-9C1D678FB184Q24328791-33AE8744-4E98-4330-B321-805EEC30DB73Q24656075-0CD71D32-0093-4FF2-9F0E-2E7A917DFC32Q26784216-C62A8B92-C5DC-4865-9E25-7387938E0F07Q28365451-0F685138-7D4E-41C9-8DDA-3D2776C20409Q28535264-6DA279F5-CE59-495C-90DE-FE0DB91103C1Q33793699-D1B9926B-990B-4D24-82B8-6EDC2B5E4DB4Q34114853-87955276-E164-48EF-A3AB-E94FAC1FE7EBQ34140428-E38DCD7E-A8FC-4DBB-BF14-C74BEFAF5C9EQ34147672-9005A941-770C-4534-B39D-59F72FD3688AQ34325033-A3D981CF-B388-43A5-8174-CA2C53B9396EQ34863976-2495044F-B36D-45FF-A38E-8486BF72B970Q34890228-B493032D-BB2D-4BED-9CF2-09A3B37A33BEQ35783757-2D455D42-ED9F-4235-BA97-302362F61F1FQ36242794-ADA753B3-0FCB-4DD9-A72B-2D87532F4953Q36563062-BF7FF62C-E447-42B3-8F52-4A7DD5086022Q36841500-54BB0F50-829E-4C07-B7CA-4CEAB8B3BE47Q37299619-CBCDF1C8-C241-41FC-9120-559B1033FEFFQ37424589-EC7E786B-F171-4315-810B-866EABF31473Q38079317-F44731B9-6EFE-4121-921B-978E58E65043Q38109663-3EFCBEDC-B23C-4914-A177-C3AF5436D9B2Q38118282-72CC97A3-B274-4D9D-A32A-610B2BB85563Q38265101-86758769-77F9-4CC3-992D-AE53740CA802Q38723317-B83E5493-1729-4076-B383-2A3B17F32FC1Q40027470-25709139-DB76-4C18-A5DF-915362D2F3CAQ42145813-AA5017BF-AC4B-41F4-81EC-6FA0C00E7A86Q42319474-2FF24250-8662-4949-8056-BD927EAC43A3Q44235981-C2D71995-1A4F-42F6-964B-5BD3B61101A0Q44360675-9C1DE69A-F142-4567-BC94-2A363FE63581Q51763431-D8E66B50-04F8-4DE4-A1C5-A1F716F24B21Q57605900-93E66D24-9101-4328-AD51-F305B672E3EEQ59133543-F65AB255-7641-4A77-A4E2-F30D4B5B8D8C
P2860
Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease.
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Low frequency of pathogenic mu ...... familial Parkinson's disease.
@ast
Low frequency of pathogenic mu ...... familial Parkinson's disease.
@en
type
label
Low frequency of pathogenic mu ...... familial Parkinson's disease.
@ast
Low frequency of pathogenic mu ...... familial Parkinson's disease.
@en
altLabel
Low frequency of pathogenic mu ...... n familial Parkinsonʼs disease
@en
prefLabel
Low frequency of pathogenic mu ...... familial Parkinson's disease.
@ast
Low frequency of pathogenic mu ...... familial Parkinson's disease.
@en
P2093
P50
P1433
P1476
Low frequency of pathogenic mu ...... familial Parkinson's disease.
@en
P2093
P304
P356
10.1097/00001756-199902050-00040
P577
1999-02-01T00:00:00Z